Impact of Modified System of Objectified Judgement Analysis (SOJA) Methodology on Prescribing Costs of ACE Inhibitors

Alabbadi, Ibrahim; Crealey, Grainne; Scott, Michael; Baird, Simon; Trouton, Tom G.; Mairs, Jill; McElnay, James

doi:10.2165/00044011-200626090-00001

Cited by 5 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This system has been a proven help to guide decision makers in arriving at more rational decisions 12. It has also been shown to provide cost savings to health care providers in the UK 13. Similar tools have also been used in Thailand to facilitate evidence-based drug selection processes for the National Essential Drug Lists with implementation of the information, Safety, administration restrictions, frequency of administrations and Efficacy (iSafE) scoring system 14…”

Section: Introductionmentioning

confidence: 99%

National Drug Formulary review of statin therapeutic group using the multiattribute scoring tool

Ramli

Aljunid

Sulong

et al. 2013

TCRM

View full text Add to dashboard Cite

Purpose: HMG-CoA reductase inhibitors (statins) are extensively used in treating hypercholesterolemia. The statins available in Malaysia include atorvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin, and fluvastatin. Over the years, they have accumulated in the National Drug Formulary; hence, the need for review. Effective selection of the best drugs to remain in the formulary can become complex due to the multiple drug attributes involved, and is made worse by the limited time and resources available. The multiattribute scoring tool (MAST) systematizes the evaluation of the drug attributes to facilitate the drug selection process. In this study, a MAST framework was developed to rank the statins based on their utilities or benefits. Methods: Published literature on multicriteria decision analysis (MCDA) were studied and five sessions of expert group discussions were conducted to build the MAST framework and to review the evidence. The attributes identified and selected for analysis were efficacy (clinical efficacy, clinical endpoints), safety (drug interactions, serious side effects and documentation), drug applicability (drug strength/formulation, indications, dose frequency, side effects, food-drug interactions, and dose adjustments), and cost. The average weights assigned by the members for efficacy, safety, drug applicability and cost were 32.6%, 26.2%, 24.1%, and 17.1%, respectively. The utility values of the attributes were scored based on the published evidence or/and agreements during the group discussions. The attribute scores were added up to provide the total utility score. Results: Using the MAST, the six statins under review were successfully scored and ranked. Atorvastatin scored the highest total utility score (TUS) of 84.48, followed by simvastatin (83.11). Atorvastatin and simvastatin scored consistently high, even before drug costs were included. The low scores on the side effects for atorvastatin were compensated for by the higher scores on the clinical endpoints resulting in a higher TUS for atorvastatin. Fluvastatin recorded the lowest TUS. Conclusion: The multiattribute scoring tool was successfully applied to organize decision variables in reviewing statins for the formulary. Based on the TUS, atorvastatin is recommended to remain in the formulary and be considered as first-line in the treatment of hypercholesterolemia.

show abstract

Section: Introductionmentioning

confidence: 99%

National Drug Formulary review of statin therapeutic group using the multiattribute scoring tool

Ramli

Aljunid

Sulong

et al. 2013

TCRM

View full text Add to dashboard Cite

show abstract

“…Using our formulary decision criteria, the P&T Committee decided to limit the ARBs on the formulary to candesartan and valsartan in 2004. The TMU's formulary decision criteria, which were similar to the System of Objectified Judgment Analysis, included appropriate indications, factors affecting patient compliance, bioavailability, interactions, clinical impact and efficacy, acquisition cost, and documentation supporting efficacy [18,19]. Candesartan was listed as the preferred agent with a high score in the formulary decision criteria due to its low acquisition cost and good documentation for hypertension, and valsartan was restricted to patients with heart failure.…”

Section: Introductionmentioning

confidence: 99%

Successful Implementation of a P&T-Approved Therapeutic Interchange Program of Angiotensin II Receptor Blockers in a Medical Center in Taiwan

et al. 2012

View full text Add to dashboard Cite

show abstract

One-Year assessment of joint procurement of pharmaceuticals in the public health sector in Jordan

Alabbadi

Qawwas

Jaafreh

et al. 2009

Clinical Therapeutics

View full text Add to dashboard Cite

Impact of Modified System of Objectified Judgement Analysis (SOJA) Methodology on Prescribing Costs of ACE Inhibitors

Abstract: The modified SOJA approach has a significant contribution to make in containing the costs of ACEIs. Applying modified SOJA as a practical method for all indications will allow the development of a unified formulary that bridges secondary and primary care.

Cited by 5 publications

References 14 publications

National Drug Formulary review of statin therapeutic group using the multiattribute scoring tool

National Drug Formulary review of statin therapeutic group using the multiattribute scoring tool

Successful Implementation of a P&T-Approved Therapeutic Interchange Program of Angiotensin II Receptor Blockers in a Medical Center in Taiwan

One-Year assessment of joint procurement of pharmaceuticals in the public health sector in Jordan

Contact Info

Product

Resources

About